Calidar Completes Enrollment for 4D Mammography Human Trial

Calidar, a company known for its advancements in precision diagnostic imaging, has completed enrollment of participants in the inaugural clinical trial of its novel 4D Mammography system. The study, done in collaboration with Baptist Health Hardin in Elizabethtown, KY, involved 61 participants and marks a significant step forward in enhancing breast cancer diagnostics.

The innovative 4D Mammography system utilizes X-ray diffraction, allowing for molecular-level imaging of breast tissue, a technique not found in traditional mammography. The aim is to better differentiate between healthy and cancerous tissue. "First-in-human is the gate that separates promise from evidence," stated Dr. Carpenter, CTO of Calidar, emphasizing the transition from theoretical potential to clinical evidence. With initial data suggesting a fourfold improvement in precision compared to 3D mammography, the team is now moving into detailed data analysis.

Initiated in August 2025, this trial aims to evaluate the system’s effectiveness in distinguishing healthy tissue from tumors. The ultimate goal is to redefine breast cancer detection methodologies and potentially reduce the frequency of unnecessary biopsies—a substantial concern, as 70-80% of the approximately 1.8 million annual breast biopsies in the U.S. yield benign results, costing over $7.4 billion in health care expenses annually.

Participation in this study was conducted under investigational use, meaning results were not applied to patient care. The collected data is being analyzed, with a peer-reviewed publication expected in the latter half of 2026. As the company prepares for broader implementation, Calidar is planning a Series A funding round aimed at supporting a larger, multi-site pivotal study, with the ultimate goal of securing FDA approval.

Baptist Health Hardin served as the clinical site for this study. The hospital, serving a ten-county area in Kentucky, facilitated the imaging of patients who required further evaluation following standard mammography. This collaboration with Calidar represents a concerted effort to advance diagnostic capabilities, potentially improving outcomes for many women facing breast cancer diagnoses.

The 4D Mammography system currently holds an investigational status and has not been cleared or approved by the FDA, thus remaining unavailable for commercial use in the U.S.